Hamlet BioPharma is a pharmaceutical company. Most research and development is carried out in the field of protein-lipid complexes, which are used in the treatment of various forms of cancer. The company has developed a tumoricidal protein-lipid complex that mainly is used in the treatment of breast cancer, bladder cancer, as well as in cases of cancer that are hard to treat. The company is based in Lund.

Quotes for Hamlet BioPharma AB

Created with Highstock 6.0.7CloseTraded Volume13. jan20. jan27. jan3. feb10. feb17. feb24. feb3. mar10. mar17. mar24. mar31. mar1.62.43.244.80200T400T600T800T

Right Now

+/-
-0.03
%
−0,76%
Latest
3.9
High
3.96
Low
3.9
Volume
4 370
Turnover (SEK)
17 119
Market Value (MSEK)
537,1
Time (Latest trade)
2025-04-03 10:52

Board

CEO

  • Catharina Svanborg

Chairperson of the Board

  • Gabriela Godaly

Board

  • Bill Hansson
  • Elisabeth Parker
  • Helena Lomberg
  • Magnus Nylen
  • Ulla Trädgårdh
  • Articles of association

    • News

    Show More

    News agencies

    Show More

    Analysis

    Videos

    Intervju med styrelseordförande Catharina Svanborg

    Interview with Catharina Svanborg Chairman of the Board/Founder

    This is HAMLET - The movie

    Hamlet Pharma - Life Sciencedagen

    Intervju med styrelseordförande Catharina Svanborg

    Interview with Catharina Svanborg Chairman of the Board/Founder

    This is HAMLET - The movie

    Hamlet Pharma - Life Sciencedagen

    Largest Owners

    Name Capital % Votes % Date
    Catharina Svanborg 34,28 74,84 2024-12-23
    Nordnet Pensionsförsäkring 6,15 2,03 2024-12-23
    Avanza Pension 5,58 1,91 2024-12-23
    Rolf Karlsson 3,68 1,22 2024-12-23
    Hans Nygren 1,84 0,61 2024-12-23
    Gramsh Gashi 1,70 0,56 2024-12-23
    Nordea Liv & Pension 1,49 0,49 2024-12-23
    Creative Invest One AB 0,83 0,27 2024-12-23
    Försäkringsaktiebolaget Skandia 0,73 0,25 2024-12-23
    Creative Networks X AB 0,50 0,17 2024-12-23
    ** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

    Insider trading

    NameTransaction DateTypeInstrumentAmountPriceValueCurrency
    Linnane Pharma AB2023-05-26Buy TransactionHamlet Pharma A 100 0003,26326 000,0SEK
    Jakob Testad2023-04-26Sell TransactionHamlet Pharma A- 100 0003,26−326 000,0SEK
    Ulla Trägårdh2022-01-18Buy TransactionHamlet BioPharma B 15 0006,1291 800,0SEK
    Mats Persson2021-07-20en-USHamlet Pharma BTU A 769139 997,0SEK
    Mats Persson2021-07-20en-USHamlet Pharma BTU B 384134 992,0SEK
    Mats Persson2021-07-23Buy TransactionHamlet Pharma A 10 0006,565 000,0SEK
    *Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

    Key Numbers

    2024-12-312024-09-302024-06-302024-06-302024-03-312023-12-312023-09-30
    Number of months that the report spans Q2 3 MonthsQ1 3 Months2024Q4 3 MonthsQ3 3 MonthsQ2 3 MonthsQ1 3 Months
    Total revenue MSEK0.000.000.000.000.000.000.00
    Earnings before interest and tax MSEK-13.98-9.94-40.54-11.30-11.98-8.93-8.33
    Profit before tax MSEK-13.89-9.77-39.82-11.04-11.80-8.65-8.33
    Net profit MSEK-13.89-9.77-39.82-11.04-11.80-8.65-8.33
    Earnings per share SEK-0.00-0.00-0.00-0.00-0.00-0.00-0.00
    Dividend per share SEK0.00
    Equity MSEK69.8157.1966.9566.9577.9947.3455.99
    Fixed assets MSEK0.370.460.570.570.540.650.62
    Intangible assets MSEK29.1731.1933.2133.2135.2337.2539.27
    Current assets MSEK35.4520.6527.2827.2836.957.8614.65
    Total asset MSEK74.9962.3071.0671.0682.7255.7664.54
    Long term liabilities MSEK0.000.000.000.000.005.005.00
    Current liabilities MSEK5.185.124.114.114.733.433.55
    Number of shares SEK177.69167.76167.76167.76167.76126.01126.01
    *Compiled data from Millistream

    Upcoming reports

    • 2025-05-22 Delårsrapport 2025-Q3

    • 2025-08-28 Bokslutskommuniké 2025

    • 2025-11-14 Delårsrapport 2026-Q1

    • 2025-11-20 Årsstämma 2025

    Annual reports, prospectus etc.